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1 Introduction 
 
The incidence of Clostridium difficile infection (CDI) in patients with inflammatory 
bowel disease (IBD) has increased over the past few decades [1, 2]. IBD patients are 
more susceptible to develop CDI and severe outcomes than non-IBD patients [3, 4]. 
Moreover, the recurrences of CDI seem to occur more frequently in IBD patients and 
the risk for recurrences increases after every CDI episode [5, 6].  
Currently the risk factors for CDI in IBD patients have only poorly established. IBD 
patients with CDI are on average younger than other patients with CDI [7]. Some 
evidence suggests that IBD-related medications and colon limited disease could 
predispose to CDI although more studies are needed to define these factors more 
clearly [5, 7, 8].  
Our study paid interest on the differences between IBD and CDI patient 
characteristics. We compared in our study IBD patients with CDI to two control 
patients groups; CDI patients without IBD and IBD patients for clarifying the 
predisposing and prognostic factors. The study could offer a way to better 
understanding for the risks of CDI in IBD patients, diagnosing and optimal treatment 
strategy in IBD patients with CDI. At the moment, diagnosis of CDI in IBD patients may 
be difficult due to overlapping clinical symptoms of CDI and IBD flare up. Moreover, 
asymptomatic colonization of the bacterium and lack of the traditional 
pseudomembranes on the mucosa of the colon may also mislead the clinician.        
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2 Review of literature 
 
2.1 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the 
gastrointestinal tract. There are two principal IBD types: Crohn’s disease (CD) and 
ulcerative colitis (Colitis ulcerosa, CU). Sometimes it may be difficult for a specialist to 
distinguish CD and CU from each other at the colonoscopy or afterwards in the 
colonoscopy biopsies. When the diagnosis cannot be clearly made after these 
processes, the condition is defined as an inflammatory bowel disease unclassified 
(IBD-U).  IBD is a lifelong idiopathic autoimmune condition with relapsing and 
remitting courses. The incidence of IBD varies geographically and has increased 
worldwide especially within the industrialized countries [1, 2]. The prevalence of CU in 
Europe is 500 per 100000 persons and for CD 320 per 100000. In the United States 
corresponding values are 250 per 100000 individuals for CU and 200 per 100000 for 
CD [1]. In Finland the incidence of IBD has increased approximately three fold since 
the 1990s. In 2008 the prevalence was 595 per 100000 individuals [9]. The onset of 
disease has two age peaks: the well-defined first peak seems to arise between the 
ages of 20 to 39, and the second between the ages of 50-70 [10]. However, the 
emergence of second peak is under dispute and poorly established [9].  
Although the exact cause of inflammatory bowel disease remains poorly understood, 
some genetic and environmental predisposing factors have been identified. Current 
opinion on the course of disease is that genetically susceptible individuals develop an 
inadequate immune response when in contact in environmental factors (Figure 1) [2]. 
The result is enhanced immune reaction against gut’s microflora. Previous studies 
have shown that the composition of normal flora in IBD-patient’s gut is altered, 
although some age-related changes also exist [11]. Altered microbiota in the intestine 
is also called dysbiosis and it has thought to play a critical role in the pathogenesis of 
inflammatory bowel disease [12]. It is not yet clearly demonstrated if dysbiosis plays a 
part in development of IBD or vice versa. There are also over 163 genetic loci 
associated with susceptibility to develop IBD [13]. 
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Figure 1. Inflammatory bowel disease (IBD) as a multifactorial disorder [14]. 
 
 
2.1.1 Crohn’s disease 
The prevalence of Crohn’s disease has increased in the past few decades, especially in 
the younger generation. CD is a progressive chronic inflammatory disease that can 
affect the entire gastrointestinal tract from mouth to anus. Usually inflammation 
persists in the terminal ileum or colon. It is characterized by segmental transmural 
lesions and granulomas on the intestinal wall. Smoking is strongly associated with CD 
[15]. There are also some genetic factors that predispose to CD. The most often 
associated gene variant with CD is NOD2 (encoding nucleotide-binding oligomerization 
domain-containing protein 2). The hallmarks of clinical symptoms include bloody 
diarrhea, abdominal pain, fatigue and weight loss. Complications may also occur, 
especially in more severe disease. These complications include fibrosis, intestinal 
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obstruction and perianal manifestations such as fistulae and abscesses [16]. Some 
studies have shown that most of the CD patients will sooner or later require a surgery 
depending on the site and activity of the disease [17].  
 
2.1.2 Ulcerative colitis 
The inflammation in the ulcerative colitis is limited to the mucosal layer of the colon 
and rectum. The most common symptom of UC is bloody diarrhea. In an active state 
of disease there may form some ulcers in a mucous membrane of the colon or rectum. 
The disease can occur at any age, but most commonly it arises later in life or in early 
adulthood [18]. The incidence of CU has increased over the world in the recent 
decades and it is more frequent than Crohn’s disease [5]. A few predisposing factors 
for CU have found including usage of NSAIDs, family history and some nutritional 
factors [18]. The effect of smoking history in patients suffering from UC is different 
compared to CD patients. It is now known that smoking is a protective agent in CU 
[18]. There is also some conflicting data according to the gender predominance in CU. 
Some sources have reported male gender to be more common among patients with 
CU, but recent studies have published some data in which female gender 
predominates [19-21].  
  
2.1.3 Treatment strategy for IBD 
A conventional treatment strategy for mild to moderate IBD is based on anti-
inflammatory drug 5-aminosalicylate (5-ASA). 5-ASA is occasionally combined with 
corticosteroids for patients who otherwise fail to achieve remission [22]. 
Immunomodulators, such as thiopurines or methotrexate, may be required for 
maintenance of remission in certain patients or in patients with more severe disease 
[13]. Thiopurines and methotrexate are effective in maintenance of remission and 
lessen the need for corticosteroid intake. Indeed, a moderate corticosteroid sparing 
impact makes these immunomodulators an important option, especially for steroid 
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dependent IBD patients [23]. One remarkable disadvantage of therapy with 
immunomodulators is a risk of leukopenia which increases susceptibility to infectious 
complications  [24].  
While systemic corticosteroids are beneficial in short-term treatment of IBD, 
especially in patients under acute IBD flare [25, 26], the long-term treatment with 
corticosteroids is limited due to vast array of adverse effects. [25]. Drawbacks of 
corticosteroid therapy are different side effects including bone loss and poor wound 
healing, which may occur particularly in prolonged use. However, among IBD patients 
the most adverse complication due to corticosteroids is that they predispose to 
infections which seem to increase the mortality rate in elderly, hospitalized IBD 
patients [27]. The risk of infection seems to depend on dose and duration of 
corticosteroid therapy, usage of immunosuppressive medication or 
immunomodulators and the patient’s underlying disease state [28] [24]. Most of the 
patients respond acutely to treatment with corticosteroids but the therapy becomes 
problematic in patients who fail to respond appropriately or become dependent on 
the usage of corticosteroids [13, 29]. In corticosteroid dependent patients, clinical 
relapses occur upon steroid withdrawal. These conditions are difficult to treat and 
may lead to a need of escalation of medical therapies from corticosteroids to biologic 
agents including anti-TNF or vedolizumab [22, 30].  
Biological therapy has shown efficacy in IBD patients. Treatment with antibodies 
targeting tumor necrosis factor alpha (anti-TNFα agents), such as infliximab and 
adalimumab, have been established in treatment of more severe IBD [13]. Previous 
studies have reported these medications to be effective especially for patients who 
have not achieved a clinical remission with conventional therapies. Furthermore, 
these therapeutics have been demonstrated to induce mucosal healing and cure 
fistulizing disease in CD patients [31]. Negative effects of TNF-alpha have also been 
reported. They include formation of autoantibodies against the medication, especially 
when used as monotherapy, eczema and the ability to reactivate latent tuberculosis 
which further can cause a serious infection [13, 32]. 
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There is no known cure for CD or CU but different medications can be used to relieve 
the symptoms and prevent complications [12]. Immunosuppressants and biologic 
agents are the cornerstones of Crohn’s disease treatment [12]. Certain antibiotics can 
be used for maintaining remission in CD or as a treatment for complications and post-
operative wound infections [12]. A lifelong medication is needed in a majority of 
patients with CU. The medication is largely the same which are used in CD including 
immunosuppressants, biologic agents and 5-ASA. Steroids are commonly used as a 
treatment to induce clinical remission in the cases of acute exacerbation in both CD 
and CU. However, steroids are not recommended to use as a maintenance therapy 
probably due to the side effect and inefficiency in prolonged use [25]. Some patients, 
who have contraindications or who do not respond to medical therapy have to 
undergo surgery [33].  
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2.2 Clostridium difficile Infection 
Clostridium difficile is an anaerobic, spore-forming gram-positive bacterium. It is the 
most common cause of antibiotic-associated diarrhea, especially among hospitalized 
patients. Healthy infants may be asymptomatic carriers of Clostridium difficile but 
usually the colonization of this bacterium decreases with age [34]. Germs can be 
transmitted through food, human and environmental sources. Clostridium difficile can 
spread from one person to another as a heat resistant spore through fecal-oral route 
and colonize the colon. Infection disease can be caused by production and further 
secretion of two pathogenic toxins (toxin A and B).  
Rates of Clostridium difficile infection (CDI) have increased since 2000, especially 
among elderly hospitalized patients [35]. However, the increase in the prevalence of 
CDI is not as great in countries, which have paid much attention on prophylactic 
effects against hospital infections (Figure 2). CDI is classically considered a nosocomial 
concern but the prevalence of the infection in community has increased worldwide 
over the past two decades [36]. Many previous studies have identified risk factors for 
hospital-acquired CDI. These include advanced age, antineoplastic chemotherapy, co-
morbidities and usage of multiple medications most importantly antibiotics and 
proton pump inhibitors (PPIs). Patients with community-acquired CDI seem to be not 
associated with these traditional risk factor [36]. As compared to nosocomial CDI, 
community-acquired infection appears to occur in younger patients who have not 
received antibiotics recently [36, 37].  
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Figure 2. Reported cases of Clostridium difficile toxin positive cases in Finland 2008 
until August 2016 (National Institute for Health and Welfare, infectious disease 
register). 
 
 
Clostridium difficile infection (CDI) rarely arises spontaneously as antibiotic usage 
usually precedes it. The most important antibiotics associated with CDI are ampicillin, 
amoxicillin, cephalosporins, clindamycin and fluoroquinolones [37]. Antibiotics have 
negative impact on the gut flora. They affect the diversity and composition of the gut 
normal microbiota and disturb colonization resistance of the colon. Weakening of this 
resistance allow C. difficile to colonize the colon and cause infection. The spectrum of 
infection may range from asymptomatic carriage and mild diarrhea to life-threatening 
pseudomembranous colitis and even bowel perforation. Clinical symptoms include 
abdominal pain, vomiting, green diarrhea, fever, leukocytosis, hypoalbuminemia and 
raised C-reactive protein [11]. There have been identified a hypervirulent strain of 
Clostridium difficile (BI/NAP1/027). In addition to toxin A and B, this 027-ribotype is 
also able to produce binary toxin, which is associated with more severe disease.  
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2.2.1 Treatment for CDI 
The first-line and conventional treatment of CDI consist of antibiotic therapy including 
metronidazole and vancomycin [37, 38]. These antibiotics have been used since 1970s 
and no resistance against these two medication has been reported [37]. The latest 
antibiotic against Clostridium difficile is fidaxomicin, which is recommended to use 
especially in recurrent infections [39]. However, great costs limit its usage. Despite the 
effective treatment with these drugs, relapses occur. The risk of recurrence for 
symptomatic CDI increases with each successive episode. It increases from 20% after 
the first episode up to 60% after multiple recurrences [37, 38]. It is still recommended 
to treat recurrences of Clostridium difficile infection with repeated course of 
antibiotics. Infections may be difficult to permanently cure probably because of re-
exposure to or reactivation of spores in the intestine, diminished antibody response to 
infection or weakened colonization resistance in the colon [37]. One way to prevent 
the recurrence of CDI (rCDI), especially in patients with mild symptoms, is to avoid 
antibiotic intake that allowed the infection to develop [37].  
There is strong evidence of efficacy of fecal microbiota transplantation (FMT) as a 
treatment for rCDI, however, little is known of the exact mechanisms of this 
treatment. Recent studies have reported effectiveness of FMT preventing relapses of 
CDI. It is thought that FMT reconstitute the normal gut flora and so a subsequent 
colonization resistance in the gut is created again [40, 41]. 
 
2.3 CDI in IBD patients 
 The incidence of CDI and its related complications in IBD-patients has increased 
rapidly over the past decades in North America and Europe [42]. These patients are at 
significantly higher risk of developing active infection than the general population [3]. 
Patients with UC have been reported to be even more susceptible to CDI than CD 
patients [6]. Previous studies have shown that IBD patients are more likely to have 
severe CDI and worse outcomes than the IBD patients without CDI. [3, 4]. These 
patients not only had a longer length of hospital stay but also higher rates of IBD flare, 
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colectomies and mortality [7, 8]. According to Nguyen et. al. the length of hospital stay 
was 65% longer in CD patients with CDI and 46% longer in UC patients with CDI [4]. 
Likewise IBD patients with CDI were found to have approximately 1.2 to 3 times higher 
risk of undergoing gastrointestinal surgery as compared to patients with IBD alone 
[43]. 
The incidence of CDI is higher in IBD patients and IBD has been shown to be an 
independent risk factor for CDI [6]. IBD patients are also likely to have additional risk 
factors that differ from conventional risk factors of non-IBD patients [6]. In fact, IBD-
related CDI patients seem to be younger than non-IBD CDI patients. These IBD 
patients usually have a disease affecting the colon and a community acquired CDI [8, 
44, 45].  
There is some evidence about IBD-associated medical factors such as steroids and 
immunosuppressants which seem to be remarkable risk factors for CDI among these 
patients. Moreover, initiation of corticosteroids in IBD-patient increased the CDI rate 
threefold compared with other immunosuppressant agents [42]. Unlike the common 
risk factor for CDI in non-IBD patients, exposure to antibiotics does not seem to play a 
critical role in triggering CDI probably because of the gut dysbiosis in patients with IBD 
[7, 42].  
In addition to disease susceptibility, IBD-patients are documented to have 33% higher 
risk to develop recurrence of CDI compared with non-IBD patients [5]. Factors that 
increase the risk for recurrence include 5-ASA use, steroid use, antibiotic and biologic 
therapy and non-ileal CD [5].  
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2.3.1 Treatment of CDI in IBD patients   
Usually both infectious disease specialists and gastroenterologists participate in the 
treatment strategy for IBD patients with CDI. According to ECCO and ACG guidelines 
metronidazole and vancomycin should be used as a first-line treatment for patients 
with mild to moderate CDI in general. The CDI in patients suffering from IBD is 
considered as a serious condition which should be treated even more aggressively 
than generally [46]. Further, treatment strategy for CDI in patients with IBD should not 
only be based on the severity of the infection but also the risk factors for poor 
outcome. One interesting consideration is the usage of immunosuppressants in IBD-
CDI patients. As previously mentioned, patients who have been using these 
medications have documented to be more susceptible to develop CDI. It can cause 
confusion whether to decrease or increase the dose of immunosuppressant in IBD 
patients during CDI. Further, Ben-Horin et. al. reported negative impacts of antibiotics 
and immunosuppressants on IBD-patients with CDI when using as a combination 
therapy [47]. They noticed that worse outcomes were achieved by patients who 
received both antibiotics and immunosuppressants compared to patients who were 
cured with antibiotics alone [47]. For now, ACG recommended continuation of 
immunosuppressants with same doses as already used during ongoing therapy. 
The exact course in the pathogenesis of CDI in IBD remains unclear. It is not known 
whether the CDI triggers an IBD flare up or if the flare up occurs independently from 
CDI and further predisposes to C. difficile colonization. It may be difficult for the 
clinicians to differentiate CDI from IBD flare because they often co-exist, the 
symptoms resemble one another and the classic pseudomembranes are rarely found. 
It is recommended to screen for CDI in every flare up in IBD [48]. It is important to 
diagnose CDI because the negative impacts on IBD. 
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3 Methods 
 
The study was approved by the institutional review board of Helsinki University 
Hospital. In this retrospective cohort study, 167 IBD patients with CDI were enrolled 
from medical records of HUS register. These patients were registered between years 
of 2008 and 2013 and data from records collected between June and July in 2016. The 
patient selection based on the clinician’s diagnosis of that time. Thus, following 
variant forms of IBD were also included in our study: Ulcerative colitis (n=105, 63% of 
all), Crohn’s disease (n=48, 29% of all) and unspecified IBD (IBD-U, n=14, 8% of all). 
Different clinical parameters including age, gender and mortality were collected. 
Exposure to commonly used medications among these patients was also investigated. 
Usage of IBD-related drugs, antibiotics, NSAIDs and PPIs during the last 3 months 
before a toxin positive CDI test were recorded. 
A control group of non-IBD related CDI patients was gathered from HUS register to 
compare the patient characteristics with the patients in IBD-CDI cohort.  The cohort 
was age- and gender-matched with our study cohort. The number of CDI recurrences 
was matched to our study cohort, thus differences in recurrence rates between these 
patient groups are not compared. 
A second control age- and gender-matched cohort of IBD-patients was gathered from 
the IBD cohort studied in the Doctoral thesis of Johanna Haapamäki [49].  
 
3.1 Statistical methods 
Patient characteristics between groups were analyzed using the chi-square test, the 
Fisher exact test and the Bonferroni multiple comparison test. One-way analysis of 
variance was used for continuous variables. A p value of <0.05 was considered 
statistically significant. All calculations were accomplished with NCSS-2000 software. 
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4 Results 
 
4.1 Patient characteristics 
A total of 167 IBD patients with CDI were included in our IBD related CDI (IBD-CDI) 
study cohort. All the patient suffered from IBD (Figure 3) and variable number of CDI 
episodes. Patient characteristics are represented in table one. In the study cohort, the 
mean age was 46.1 (range 6.4-91.9 years). Age and gender matched control cohorts of 
non-IBD related CDI (CDI cohort) and IBD (IBD cohort) were gathered also (Table 1).  
 
 
 
 
 
 
 
 
Figure 3. Different types of IBD. Most of the patients in the IBD-CDI cohort 
suffered from CU. 
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Table 1. Characteristics of the patients. 
 IBD* and CDI 
n=167 
CDI **  and no IBD 
n=166 
IBD* 
n=157 
Gender (Males n (% 
of total) ) 
85 (50,9) 78 (47,0) 77 (49,0) 
Age (average±SD) yrs 46,1±21,0 47,4±21,5 45,9±19,8 
    
    
*IBD group includes patients with Crohn’s disease, colitis ulcerosa and unspecified 
colitis. These groups include age and sex selected control patients for IBD and CDI 
patients. **CDI=Clostridium difficile infection. 
 
Table 2. The overall count of CDI episodes in IBD patients with CDI and patients 
without IBD. 
 One 
episode 
 
Two 
episodes 
Three 
episodes 
Four 
episodes 
Five  
episodes 
Seven  
episodes 
Total 
IBD+CDI 
(n) 
116
  
26 15 6 4 0 167 
CDI+no 
IBD (n) 
115
  
24 13 7 6 1 166 
 
 
 
4.2 Recurrence of CDI (rCDI) 
The overall count of CDI episodes are shown in Table 2.  In both cohorts the range of 
rCDI was between two to seven episodes and no significant difference in recurrence 
rate was evident between two patient groups (IBD-CDI and CDI cohorts). 
 
4.2.1 Genders 
We compared the recurrence rate of CDI between genders (Figure 4). A total of 524 
episodes in IBD-CDI and CDI cohorts were initially analyzed. Together these cohorts 
showed CDI recurrences to occur more often in females than in men (p=0.0367). A 
similar trend was seen within the IBD-CDI cohort alone although statistical significance 
was not reached.   
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Figure 4. Clostridium difficile episodes in males and females (IBD-CDI and CDI cohorts 
merged). *p= 0,0367 male vs female in three or more episodes. 
 
 
4.2.2 IBD forms 
In our study cohort, the most common form of IBD was CU (Figure 3). The recurrence 
of CDI was most rarely seen in patients with CD as compared to other forms of IBD 
(Figure 5).  
 
Figure 5. Clostridium difficile episodes (%) in variant forms of IBD patients.  
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4.2.3 Medical therapy 
Drug usage in the IBD-CDI cohort was recorded for three months preceding an 
infection episode for available cases (Table 3). Corticosteroids were the most 
commonly used medication in the IBD-CDI cohort. The proportion of 5-ASA and PPI 
users was also high. About half of the patients had been exposed to systemic 
corticosteroid and few to local corticosteroid before CDI. Proportionally the usage of 
systemic corticosteroid was higher in patients with two or more CDI episodes, 
although statistical significance was not reached. Patients with no corticosteroid 
intake were not as susceptible to have a recurrent infection. Despite the usage of 5-
ASA and PPIs, other medications in our study did not appear to have a similar impact 
on the rate of recurrence of CDI within the IBD-CDI cohort. 
 
Table 3. Clostridium difficile-infection episodes in IBD patients using different 
treatments.  
 Once Twice Three or more 
episodes 
5-ASA  
users % (n/total) 
  
65,8% (73/111) 
  
73,1% (19/26) 
 
75,0% (18/24) 
Corticosteroid users 
systemic % (n/total) 
local % (n/total) 
both % (n/total) 
 
52,3% (57/109) 
5,5% (6/ 109) 
5,5% (6/109) 
 
56,0% (14/25) 
8,0% (2/25) 
20,0% (5/25) 
 
58,3% (14/24) 
8,3% (2/24) 
4,2% (1/24) 
Tiopurines  
users % (n/total) 
 
36,4% (40/110) 
 
38,5% (10/26) 
 
29,2% (7/24) 
Infliximab  
users % (n/total) 
 
12,7% (14/110) 
 
11,5% (3/26) 
 
4,2% (1/24) 
Adalimumab 
users % (n/total) 
 
3,6% (4/110) 
 
0/26 
 
0/24 
Vedolitsumab  
users (n/total) 
 
0/110 
 
0/26 
 
0/24 
NSAID  
users % (n/total) 
 
28,2% (31/110) 
 
15,4% (4/26) 
 
25,0% (6/24) 
PPI 
users % (n/total) 
 
47,3% (52/110) 
 
53,8% (14/26) 
 
45,8% (11/24) 
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Examining the potential predisposing medical factors for CDI in IBD patients, we 
compared the usage of different IBD-related drugs between IBD-CDI and IBD cohorts. 
The systemic corticosteroid usage was twice as high in IBD-CDI as in IBD cohort alone 
(p<0.01). The usage of 5-ASA was lower in IBD-CDI cohort. Other medications 
presented in the table did not appear to affect in the same way (Table 4). 
 
Table 4. Use of drugs in IBD-CDI and IBD patients. 
 IBD and CDI IBD 
5-ASA  
users % (n/total) 
 
68,3% (110/161) 
 
75,2% (118/157) 
Corticosteroids (systemic) 
users % (n/total) 
 
61,4% (97/158)*** 
 
28,0% (44/157) 
Tiopurines  
users % (n/total) 
 
35,6% (57/160) 
 
30,6% (48/157) 
Infliximab 
users % (n/total) 
 
11,3% (18/160) 
 
8,3% (13/157) 
***p<0.01 
 
IBD patients in IBD-CDI cohort had also frequently received antibiotic therapy during 
the previous three months before a CDI episode as shown in Table 5. The use of broad 
spectrum antibiotics seem to be common in IBD patients during the diagnosis of CDI, 
but CDI can appear without any predisposing antibiotics. No significant difference was 
found in different antibiotics and different types of IBD.  
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Table 5. Antibiotic use of IBD patients during three months before the diagnosis of 
CDI. 
 Crohn’s 
disease 
(n=6) 
Colitis 
ulcerosa 
(n=8) 
IBD 
unclassi
fied 
(n=2) 
Total % of all 
patients 
No antibiotic  66,7% 0% 0% 25,0% 
Ciprofloxacin 16,7% 37,5% 0% 25,0% 
Ciprofloxacin and 
metronidazole 
0 % 12,5% 100,0% 18,8% 
Cephalosporin, 
clindamycin or 
meropeneemi etc 
33,3% 12,5% 0% 12,5,3% 
Amoxicillin 3,3% 12,5% 0% 6,3% 
Metronidazole or 
vanocmycin 
3,3% 25,0% 0% 12,5% 
 
 
4.3 Mortality 
We identified no statistically significant difference in the rates of CDI-related mortality 
between IBD-CDI and non-IBD patients in our study. IBD patients had even less 
mortality compared to non-IBD patients with following rates: 1 of IBD-CDI patients 
(0.6%) died during the next 7 days and 3 (1.8%) during the next 30 days. The rates 
among non-IBD patients were slightly higher with 3 (1.9%) patients during the next 7 
days and 9 (5.6%) during the next 30 days. Altogether, short-term survival (30 days 
post-infection) after CDI episode was 97.6% in IBD-related CDI and 91.9% in non-IBD 
related CDI. 
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5 Discussion 
 
At present, IBD-related CDI is a poorly understood entity associated with dismal 
outcome. Previous studies have shown that the recurrence of CDI is more common in 
IBD patients and is related to poorer prognosis. Different risk factors of CDI have been 
investigated to enhance the prognosis of IBD patients. However, little is known about 
the risk factors for increased incidence of rCDI in IBD patients.  
Razik et. al. demonstrated in their retrospective cohort study that recurrences are 
likely to occur 33% more frequently among IBD patients as compared to non-IBD CDI 
patients. However, conflicting data about the rCDI and its risk factors in IBD patients 
exists.  
In our IBD-related CDI cohort the recurrence rate of CDI was lowest in patients with 
CD. Recurrences seemed to occur more often in other forms of IBD, such as in CU and 
IBD-U. The manifestation of the disease in these variant forms usually is limited to the 
colon where the Clostridium difficile bacterium colonizes in contrast to CD which can 
affect any parts of the dietary tract. Hypothetically, one would expect that a colon-
manifesting process could set up the premises for CDI colonization, which could 
explain the greater prevalence of recurrent infections in other forms of IBD [5]. The 
greater prevalence of CDI episodes in the colon manifesting disease could also be 
derived from the antimicrobial effects of 5-ASA on the gut microflora. It has been 
hypothesized that 5-ASA seems to develop dysbiosis which together with the colon 
affecting disease could make the patients even more susceptible to recurrence of CDI 
[50].  
Comparing genders in IBD-CDI and CDI cohorts together, our study revealed females 
to be more susceptible to recurrence of CDI than men. The reason for a greater 
susceptibility to CDI may lie on the female’s greater tendency to suffer urinary tract 
infections. The cure and prevention of urinary tract infection may lead to a greater 
consumption of antibiotics, which are potential predisposing factors for CDI in general.  
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Previous studies have reported antibiotics not to be a critical risk factor for CDI in IBD 
patients. These studies have found antibiotic exposure to occur only 40-60% of IBD 
patients with subsequent CDI [7]. In our study cohort, majority of the patients (75.0%) 
were exposed to antibiotics in the past three months before CDI diagnosis. 
Interestingly, some of the antibiotics were given to patients due to other reasons than 
underlying IBD while others due to a flare up of IBD. While almost all antibiotics have 
been associated to CDI-related diarrhea , the most common association have been 
noticed to be with only certain antibiotics including fluorokinolones, which are 
commonly used, as in our cohort, to relieve the symptoms in IBD [6]. So, some of the 
same antibiotics which most often cause CDI-related diarrhea are used as a treatment 
in IBD patients who already have increased risk to develop CDI. The indications for 
antibiotics usage should be investigated more specifically in the future in order to 
clarify the effects of IBD-related antibiotics on CDI. 
In addition to antibiotics, other IBD-related medications have also been associated 
with recurrent episodes of CDI. IBD patients with rCDI have often received recent 
therapies with 5-ASA, corticosteroids, and biologic therapy more frequently than IBD 
patients without rCDI. However, these medications, especially corticosteroids are 
usually used by IBD-patients with active disease. Since both immunosuppressants and 
IBD itself have been reported to increase the risk for CDI more studies are needed to 
define the independence of these predisposing factors [5].  
Corticosteroids have been used for a long time as a conventional treatment of IBD due 
to its effectiveness in a rapid resolution of IBD symptoms. However, previous studies 
have shown steroid usage to cause even three-fold increase in a risk to develop CDI 
and also worse clinical outcomes in patients with concomitant IBD and CDI [51] [7]. In 
our study, the most striking finding was the difference in the usage of corticosteroids 
in the IBD-CDI and IBD cohorts. In our IBD-CDI cohort as much as 61.4% of all patients 
had used systemic corticosteroids during the previous three months preceding a CDI. 
The proportion of systemic corticosteroid users in the IBD cohort was only 28.0%. In 
addition to greater consumption of systemic corticosteroids the usage was even 
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greater when examining the recurrence infections in the IBD-CDI cohort (Table 3). So, 
the use of corticosteroids seems not only to increase the risk for CDI but also for 
recurrence infections. However, predisposing characteristic could as well arise due to 
an inadequate host immune response, which already exists because of the underlying 
disease. Thus corticosteroids could as well make the IBD patients even more 
susceptibility to CDI. So, our results about the corticosteroid’s predisposing effects to 
infections could support previous studies well. 
To avoid complications of steroid use and optimize the therapy in IBD patients, other 
medications have been gaining popularity as a second-line therapy among clinicians. 
These therapeutic opportunities include immunosuppressants and biologics. Zhang et. 
al. suggest that causes for the increased incidence of CDI in IBD patients may lie on the 
therapies of these drugs. Some findings show that immunosuppressants may have a 
mild predisposing effect on CDI but conflicting data also exist [42]. Moreover, 
Infliximab but not adalimumab have been noticed to elevate the risk for CDI among 
IBD paitents. The usage of immunosuppressants and biologics, such as vedolizumab or 
anti-TNF-α antibodies, is not related to increased risk for CDI in patients in accordance 
to our study. However, these therapies were not used by many patients in our cohort.  
In our IBD-CDI cohort the consumption of 5-ASA and PPIs was quite high. The 
proportion of PPI and 5-ASA users in the IBD-CDI cohort was 48.1% and 68.3%, 
respectively. The usage of PPIs has long been known to increase the risk for CDI in 
general. Thus, a great consumption of PPIs detected in our data could further support 
its predisposing effect to CDI shown in previous studies. Previous studies have 
recorded 5-ASA to be associated with rCDI [5]. However, correlation between 5-ASA 
and recurrence infections cannot be directly detected. The consumption of NSAIDs 
was not common in our study and it seemed not to directly influence to development 
of CDI (Table 3).  
Many previous studies have been considering the effects of CDI in IBD patient 
outcomes, such as in mortality. They have shown mortality rates to be twice higher in 
IBD patients with CDI as compared to non-IBD patients with CDI, and even four-fold 
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higher than in an inpatient with IBD alone [52]. However, there are also other studies 
which have found mortality rates to be equal or non-significantly difference between 
these patients [8]. In our study, significant differences between these two groups 
were not noticed. Moreover, IBD patients with CDI seem to have even less mortality 
compared to non-IBD CDI patients. This favorable mortality rate among IBD-related 
cases may arise due to traditional risk factors, including other co-morbidities, for non-
IBD related CDI. IBD may often be the only underlying disease among patients with 
IBD alone, while non-IBD CDI patients are having more frequently co-morbidities. 
One of the most important advices for all clinicians is to avoid using unnecessary 
antibiotics. It is also important for the clinicians to be able to differentiate CDI from 
IBD flare. Sometimes it may remain unclear whether the IBD flare occurs 
independently from CDI or has CDI triggered the flare up. Clinicians should accurately 
document each case with rapid diagnosis and subsequent adequate therapy. Routine 
stool sample screening for CDI in each case with characteristics of IBD exacerbation or 
infectious colitis is recommended before giving any antibiotics.  
Since evidence based studies are disputable, there are no clear guidelines for the 
treatment of rCDI in IBD patients. So far, it is recommended to treat IBD patients with 
CDI in a similar way than the non-IBD patients with CDI alone. Here we have gathered 
and analyzed a retrospective cohort of Finnish IBD patients with CDI and compared 
patient characteristics, risk factors and CDI recurrence with IBD patients and non-IBD 
related CDI patients derived from medical records. Our study provides more insight 
into the poorly characterized CDI recurrence nature, rate and prognosis among IBD 
patients. The strengths of our study were a large IBD-CDI cohort (167 patients) with 
two different control cohorts (CDI and IBD cohorts). The weakness of our study was 
ignorance of IBD cohort’s history of CDI infections and our inability to compare disease 
activity between the IBD-CDI and IBD cohort. 
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6 Conclusions 
 
According to our study, the recurrence of CDI is more common among female patients 
with or without underlying IBD. We highlight systemic corticosteroid-intake as a major 
risk factor for CDI between IBD patients. Moreover, higher corticosteroid-intake was 
associated with higher risk of recurrence. However, we identified no significant 
difference in the mortality rate between these groups. More prospective studies are 
required to evaluate different risk factors for CDI in IBD patients. 
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